CONCERT PHARMACEUTICALS Stock as Big Money Enter, Sentiment at 1.64

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Corporate Logo

Positions for CONCERT PHARMACEUTICALS (NASDAQ:CNCE)

“Big money sentiment for CONCERT PHARMACEUTICALS (NASDAQ:CNCE) in 2018 Q2 increased to 1.64, according to SEC filings. That’s up 0.27, from 2018Q1’s 1.37. 69 funds opened new or increased equity positions, while 42 decreased and sold their holdings in CONCERT PHARMACEUTICALS so the sentiment is positive. These funds own 16.41 million shares, that’s down from 16.64 million shares in 2018Q1. Funds holding CONCERT PHARMACEUTICALS in top 10 changed to 0 from 1 for a decrease of 1. In total 18 funds closed positions, 24 reduced and 45 increased. Also 24 funds bought new CONCERT PHARMACEUTICALS stakes.

Most CONCERT PHARMACEUTICALS Shareholders

Bvf Inc Il owns 1.82 million shares in CONCERT PHARMACEUTICALS as of 2018 Q2. As of 2018 Q2, 29,821 shares of CONCERT PHARMACEUTICALS are owned by Senzar Asset Management Llc. Ingalls & Snyder Llc reported 1.34 million shares. Knott David M revealed 51,557 shares position in CONCERT PHARMACEUTICALS. The United Kingdom-based fund Gsa Capital Partners Llp holds 123,700 shares or 0.1% of their equity exposure.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company.The firm is worth $293.34 million. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders.Currently it has negative earnings. The companyÂ’s clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with AlzheimerÂ’s disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis.

The stock increased 0.40% or $0.05 during the last trading session, reaching $12.52.Concert Pharmaceuticals, Inc. is downtrending after having declined 5.89% since December 8, 2017. CNCE has 308,863 volume or 41.25% up from normal. CNCE underperformed the S&P 500 by 21.51%.

On March, 7. Investors expect Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) to report its quarterly earnings, according to RTT. Last year’s EPS was $-0.26, while now analysts expect change of 184.62 % down from current $-0.74 EPS. 0.00 % EPS growth is what analysts predict. $-0.74 EPS was reported for last quarter.

Axa reported 17,300 shs stake. Fund Sa owns 0% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 14,500 shs. Northern Corporation reported 674,923 shs or 0% of all its holdings. Tower Rech Cap Lc (Trc) has 4,537 shs for 0% of their capital. Moreover, Renaissance Techs Ltd Liability has 0.01% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 494,200 shs. State Of New Jersey Common Pension Fund D reported 0% stake. Sei Communication holds 5,177 shs or 0% of its capital. Rhumbline Advisers, Massachusetts-based fund reported 21,637 shs. Senzar Asset Management Ltd Liability Co invested 1.45% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Comml Bank Of Montreal Can reported 0% of its capital in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% of its capital in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 2,419 shs. Quantbot Technologies Lp reported 2,290 shs stake. Dimensional Fund Advsr Limited Partnership holds 943,442 shs or 0.01% of its capital. Commercial Bank Of New York Mellon accumulated 170,848 shs. Millennium Mgmt Ltd Liability Corporation reported 659,152 shs.

Concert Pharmaceuticals, Inc. registered $53,106 net activity with 3 insider purchases and 1 sale since July 9, 2018. On Wednesday, November 14 a trade for 1,000 shs valued at $11,931 was made by Auchincloss Thomas G. On Thursday, November 15 the insider ALDRICH RICHARD bought $591,262.

For more Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) news posted recently go to: Seekingalpha.com, Businesswire.com, Bizjournals.com, Seekingalpha.com or Streetinsider.com. The titles are as follows: “Concert Pharmaceuticals: At 52 Week Lows With Upcoming Catalysts – Seeking Alpha” posted on October 18, 2016, “Concert Pharmaceuticals to Participate at Upcoming Investor Conferences – Business Wire” on November 07, 2018, “King Street Properties proposes life science R&D complex in Allston near Harvard SEAS – Boston Business Journal” with a publish date: August 30, 2018, “Concert Pharmaceuticals Inc.’s (CNCE) CEO Roger Tung on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” and the last “Concert Pharma (CNCE) Announces Advancement of Novel Drug Candidate in Schizophrenia – StreetInsider.com” with publication date: February 28, 2018.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.